Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

J&J’s MS drug ponesimod receives approval in the US

J&J’s MS drug ponesimod receives approval in the US Now that Ponvory has received regulatory approval, it will enter an increasingly crowded market, with rivals including Novartis’ SLP receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod).

Bedrock announces a number of new hires

Bedrock announces a number of new hires Barton has previous sales and marketing experience gained from roles at AstraZeneca, Baxter, Abbott, AbbVie and Novartis. ... He worked at Novartis for a period of four years, most recently as community team leader, cardiovascular.

Novartis’ canakinumab misses the mark in previously treated NSCLC

Novartis’ canakinumab misses the mark in previously treated NSCLC Novartis is continuing two additional studies of canakinumab in NSCLC, in the first-line and adjuvant settings. ... Previously, Novartis had attempted to expand the use of canakinumab as a potential cardiovascular treatment.

Yescarta gains first FDA approval for indolent follicular lymphoma

Yescarta gains first FDA approval for indolent follicular lymphoma Also approved for the treatment of large B-cell lymphoma is Novartis’ rival CAR-T therapy Kymriah (tisagenlecleucel) and Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), which are both approved ... An approval in the first-line

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA Novartis Gene Therapies and NHS England have reached a ‘landmark’ deal for Zolgensma gene therapy that gives patients with spinal muscular atrophy (SMA) access to the innovative treatment. .

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...